SCHEMBL15929239

SCHEMBL15929239

CC(C)(C)c1ccc(-c2c/c(=N\O)ss2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
TYR P14679 1/20 0.36
KIF11 P52732 3/20 0.36
ALDH1A1 P00352 3/20 0.36
KMT2A Q03164 2/20 0.36
MITF O75030 1/20 0.36
TP53 P04637 1/20 0.36
FGF23 Q9GZV9 1/20 0.36
ASIC1 P78348 1/20 0.35
KDM4E B2RXH2 2/20 0.35
SLC22A2 O15244 1/20 0.34
SLC22A1 O15245 1/20 0.34
SLC22A3 O75751 1/20 0.34
PRKDC P78527 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
HPGD P15428 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23390674 0.78 HDAC3 (0.55) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL23390671 0.78 HDAC3 (0.55) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL15928850 0.73 HDAC3 (0.58) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL15929240 0.73 PRKDC (0.41) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL19735284 0.66 APP (0.48) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL23409126 0.66 HDAC3 (0.53) KMT2AHDAC3HDAC4HDAC1HDAC7
SCHEMBL26915 0.65 KIF11 (0.70) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL3423876 0.65 KIF11 (0.70) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL4671362 0.64 LMNA (0.48) LMNATYRKIF11ALDH1A1KMT2A
SCHEMBL15123780 0.63 PRKDC (0.60) LMNATYRKIF11ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023142996-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT 上海岸阔医药科技有限公司 2023-08-03 WO disclosed
US-10023555-B2 NSAIDs derivatives and uses thereof RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2018-07-17 US disclosed
US-10023555-B2 NSAIDs derivatives and uses thereof RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2018-07-17 US disclosed
US-9688607-B2 No- and H2S-releasing compounds RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2017-06-27 US disclosed
US-20170174651-A1 Method of Priming Plants Against Abiotic Stress Factors CYPRUS UNIVERSITY OF TECHNOLOGY (CY) 2017-06-22 US disclosed
US-20170174651-A1 Method of Priming Plants Against Abiotic Stress Factors CYPRUS UNIVERSITY OF TECHNOLOGY (CY) 2017-06-22 US disclosed
US-20150376162-A1 NSAIDs DERIVATIVES AND USES THEREOF RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2015-12-31 US disclosed
US-20140221316-A1 NO- AND H2S- RELEASING COMPOUNDS RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2014-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221316-A1 NO- AND H2S- RELEASING COMPOUNDS PTGS1, NOS2, NOS1 LMNA 4788/4885TYR 2255/4885KIF11 4574/4885
US-10023555-B2 NSAIDs derivatives and uses thereof PTGES, PTGES3, PTGS1 LMNA 3842/4885TYR 1672/4885KIF11 4533/4885
US-20150376162-A1 NSAIDs DERIVATIVES AND USES THEREOF PTGES, PTGES3, PTGS1 LMNA 3842/4885TYR 1672/4885KIF11 4533/4885
US-20170174651-A1 Method of Priming Plants Against Abiotic Stress Factors NOS2, NOS1, HSF1 LMNA 4091/4885TYR 2670/4885KIF11 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.